Chiang, Chi-Lu
Yang, Huai-Che
Liao, Ying-Ting
Luo, Yung-Hung
Wu, Yuan-Hung
Wu, Hsiu-Mei
Chen, Yuh-Min
Funding for this research was provided by:
National Science and Technology Council, Taiwan (111-2926-I-075-501-G)
Article History
Received: 15 October 2023
Accepted: 14 November 2023
First Online: 20 November 2023
Declarations
:
: This study was approved by the Institutional Review Board of Taipei Veterans General Hospital, Taiwan (approval number: 2023-06-016CC).
: Written informed consent was waived due to retrospective design.
: Not appliable.
: CLC has received honoraria from AstraZeneca, Boehringer Ingelheim, Pfizer, and Roche. YHL has received honoraria from AstraZeneca, Boehringer Ingelheim, and Pfizer.YMC has received honoraria from Boehringer Ingelheim, Eli Lilly, Roche/Genentech/Chugai, MSD, Pfizer, Novartis, BMS, Ono Pharmaceutical, AstraZeneca, and Takeda Oncology and provided advisory services to Boehringer Ingelheim, Eli Lilly, Roche/Chugai, MSD, AstraZeneca, and Takeda Oncology.The other authors declare no conflicts of interest relevant to the content of this manuscript.